Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
508655
Reference Type
Journal Article
Title
The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance
Author(s)
Papakonstantinou, E; Karakiulakis, G
Year
2009
Is Peer Reviewed?
Yes
Journal
British Journal of Pharmacology
ISSN:
0007-1188
EISSN:
1476-5381
Volume
157
Issue
7
Page Numbers
1111-1127
Language
English
PMID
19508395
DOI
10.1111/j.1476-5381.2009.00279.x
Web of Science Id
WOS:000268260900002
Abstract
The extracellular matrix (ECM) plays a significant role in the structure and function of the lung. The ECM is a three-dimensional fibre mesh, comprised of various interconnected and intercalated macromolecules, among which are the glycosaminoglycans (GAG). GAG are long, linear and highly charged, heterogeneous polysaccharides that are composed of a variable number of repeating disaccharide units (macromolecular sugars) and most of them, as their name implies, have a sweet taste. In the lung, GAG support the structure of the interstitium, the subepithelial tissue and the bronchial walls, and are secreted in the airway secretions. Besides maintaining lung tissue structure, GAG also play an important role in lung function as they regulate hydration and water homeostasis, modulate the inflammatory response and influence lung tissue repair and remodelling. However, depending on their size and/or degree of sulphation, and their immobilization or solubilization in the ECM, specific GAG in the lung either live up to their sweet taste/name, supporting normal lung physiology, or they are associated to 'bitter' effects, related to lung pathology. The present review discusses the biological role of GAG in the lung as well as the involvement of these molecules in various respiratory diseases. Given the great structural diversity of GAG, understanding the changes in GAG expression that occur in lung diseases may lead to novel targets for pharmacological intervention in order to prevent and/or to treat a range of lung diseases.
Keywords
glycosaminoglycans; pulmonary fibrosis; pulmonary hypertension; asthma; COPD; hyaluronic acid; hyaluronic acid synthases; hyaluronidases; lung; diseases; hyaluronic acid receptors; pulmonary arterial-hypertension; smooth-muscle-cells; growth-factor-beta; chondroitin sulfate proteoglycan; exercise-induced; bronchoconstriction; mammalian hyaluronan synthases; chemokine; gene-expression; kappa-b translocation; protein-receptor-ii; heparan-sulfate
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity